CSO and VP Regulatory resign; shareholders authorize reverse split and large issuances

Shuttle Pharmaceuticals Holdings, Inc.

Dr. Anatoly Dritschilo resigned as CSO and director effective May 9, 2025; no disagreement cited.
Michael P. Vander Hoek resigned as VP Regulatory effective June 10, 2025; no disagreement cited.
Shareholders approved reverse stock split at ratio from 1-for-3 to 1-for-100.
Approved increase in equity plan shares by 5,000,000 and issuances of >19.99% stock on note conversion.
Approved issuances of >20% stock on convertible preferred offering and equity line of credit.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael P. Vander Hoek

Vice President, Regulatory

SHPH · Shuttle Pharmaceuticals Holdings, Inc.

Effective: 2025-06-10
Filed: May 15, 2025, 7:59 PM ET

On May 9, 2025, Michael P. Vander Hoek submitted his resignation from the position of Vice President, Regulatory, of the Company, effective June 10, 2025.

Departed

Dr. Anatoly Dritschilo

Chief Scientific Offer and director

SHPH · Shuttle Pharmaceuticals Holdings, Inc.

Effective: 2025-05-09
Filed: May 15, 2025, 7:59 PM ET

On May 9, 2025, Dr. Anatoly Dritschilo, resigned as Chief Scientific Offer and director of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael P. Vander Hoek resigned as Vice President, Regulatory at Shuttle Pharmaceuticals Holdings, Inc..

Action: resigned
Role: Vice President, Regulatory

Exact text from the filing

On May 9, 2025, Michael P. Vander Hoek submitted his resignation from the position of Vice President, Regulatory, of the Company, effective June 10, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Anatoly Dritschilo resigned as Chief Scientific Offer and director at Shuttle Pharmaceuticals Holdings, Inc..

Action: resigned
Role: Chief Scientific Offer and director

Exact text from the filing

On May 9, 2025, Dr. Anatoly Dritschilo, resigned as Chief Scientific Offer and director of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”), effective immediately.

View on SEC.gov

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-010964

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.